Amgen is fighting to keep Tavneos on the market, pushing back against an FDA withdrawal proposal tied to alleged clinical trial misconduct at its subsidiary ChemoCentryx.
Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth keeping on the market.
